1Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
2Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Beijing, China
3Institute of Research and Clinical Innovations, Neusoft Medical Systems Co., Ltd, Shanghai, China
Presenting Author: Weipeng Zhang
Synopsis
Motivation:
Goals:
Approach:
Results:
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.
To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 [doi]
2. Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331-357. doi:10.6004/jnccn.2024.0035 [doi]
3. Chen, Z., Huang, M., Lyu, J., Qi, X., He, F., & Li, X. (2023). Machine learning for predicting breast-conserving surgery candidates after neoadjuvant chemotherapy based on DCE-MRI. Frontiers in Oncology, 13, 1174843. DOI: 10.3389/fonc.2023.1174843 [doi]
4. Xiong, Q., Zhou, X., Liu, Z., Lei, C., Yang, C., Yang, M., ... & Wang, K. (2020). Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy. Clinical and Translational Oncology, 22(1), 50-59.DOI: 10.1007/s12094-019-02109-8 [doi]